Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript

被引：0

作者：

Sophie Voruz

Sabine Blum

Laurence de Leval

Jacqueline Schoumans

Françoise Solly

Olivier Spertini

机构：

[1] Lausanne University Hospital (CHUV),Service and Central Laboratory of Hematology

[2] Centre Hospitalier Universitaire Vaudois and University of Lausanne,Service and Central Laboratory of Hematology

[3] Lausanne University (UNIL),Institute of Pathology, Department of Laboratory Medicine and Pathology

[4] Lausanne University Hospital and Lausanne University,Oncogenomics laboratory

[5] Lausanne University Hospital (CHUV),undefined

来源：

Biomarker Research | / 9卷

关键词：

Relapsed/refractory B-cell precursor acute lymphoblastic leukemia; Adult B-cell lymphoma/leukemia; Targeted treatment; Chemotherapy regimen; Daratumumab; CD38; venetoclax; Bcl-2; Refractory disease; Immunotherapies;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) has a very poor prognosis with a median overall survival of four to nine months. Achieving a complete molecular response is most often required to obtain a sustained leukemia-free survival after allogeneic hematopoietic stem cell transplantation. Immunotherapies targeting CD19, CD20, or CD22 are very efficient in achieving this goal. However, in the absence of the expression of these immunotherapeutic targets by lymphoblasts, treatment options are extremely scarce. We report the successful treatment of a 26-year-old man who suffered R/R, CD19, CD20, and CD22 negative B-ALL targeting Bcl-2 and CD38 by combining venetoclax and daratumumab with chemotherapy.

引用

共 50 条

[31] Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial
Yajing Zhang
Yao Wang
Yang Liu
Chuan Tong
Chunmeng Wang
Yelei Guo
Dongdong Ti
Qingming Yang
Shen Qiao
Zhiqiang Wu
Weidong Han
Leukemia, 2022, 36 : 189 - 196
[32] CD56-positive B cell precursor acute lymphoblastic leukemia harboring KMT2A-AFF1 rearrangement developed in a pregnant woman successfully treated with allogeneic hematopoietic cell transplantation
Hisao Nagoshi
Kayo Toishigawa
Tomoko Inoue
Yoshiko Okikawa
Takahiko Miyama
Takakazu Kawase
Taro Edahiro
Kyoko Kazihara
Hiromi Nakagawa
Aiko Yamaoka
Mitsunori Noma
Teruhisa Fujii
Noriyasu Fukushima
Tatsuo Ichinohe
Journal of Hematopathology, 2020, 13 : 47 - 49
[33] CD56-positive B cell precursor acute lymphoblastic leukemia harboring KMT2A-AFF1 rearrangement developed in a pregnant woman successfully treated with allogeneic hematopoietic cell transplantation
Nagoshi, Hisao
Toishigawa, Kayo
Inoue, Tomoko
Okikawa, Yoshiko
Miyama, Takahiko
Kawase, Takakazu
Edahiro, Taro
Kazihara, Kyoko
Nakagawa, Hiromi
Yamaoka, Aiko
Noma, Mitsunori
Fujii, Teruhisa
Fukushima, Noriyasu
Ichinohe, Tatsuo
JOURNAL OF HEMATOPATHOLOGY, 2020, 13 (01) : 47 - 49
[34] Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial
Zhang, Yajing
Wang, Yao
Liu, Yang
Tong, Chuan
Wang, Chunmeng
Guo, Yelei
Ti, Dongdong
Yang, Qingming
Qiao, Shen
Wu, Zhiqiang
Han, Weidong
LEUKEMIA, 2022, 36 (01) : 189 - 196
[35] Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study
Pan, Jing
Tang, Kaiting
Luo, Yuechen
Seery, Samuel
Tan, Yue
Deng, Biping
Liu, Feng
Xu, Xiuwen
Ling, Zhuojun
Song, Weiliang
Xu, Jinlong
Duan, Jiajia
Wang, Zelin
Li, Chunyu
Wang, Kai
Zhang, Yibing
Yu, Xinjian
Zheng, Qinlong
Zhao, Liping
Zhang, Jiecheng
Chang, Alex H.
Feng, Xiaoming
LANCET ONCOLOGY, 2023, 24 (11): : 1229 - 1241
[36] Impact of Consolidative Unrelated Cord Blood Transplantation on Clinical Outcomes of Patients With Relapsed/Refractory Acute B Lymphoblastic Leukemia Entering Remission Following CD19 Chimeric Antigen Receptor T Cells
Xu, Qianwen
Xue, Lei
An, Furun
Xu, Hui
Wang, Li
Geng, Liangquan
Zhang, Xuhan
Song, Kaidi
Yao, Wen
Wan, Xiang
Tong, Juan
Liu, Huilan
Liu, Xin
Zhu, Xiaoyu
Zhai, Zhimin
Sun, Zimin
Wang, Xingbing
FRONTIERS IN IMMUNOLOGY, 2022, 13
[37] Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy Targeting CD19 and CD22, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study
Amrolia, Persis J.
Wynn, Robert
Hough, Rachael E.
Vora, Ajay
Bonney, Denise
Veys, Paul
Chiesa, Robert
Rao, Kanchan
Clark, Liz
Al-Hajj, Muhammad
Cordoba, Shaun P.
Onuoha, Shimobi
Kotsopoulou, Ekaterini
Khokhar, Nushmia Z.
Pule, Martin
Peddareddigari, Vijay G. R.
BLOOD, 2019, 134
[38] Simultaneous Targeting of CD19 and CD22: Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study
Amrolia, Persis J.
Wynn, Robert
Hough, Rachael
Vora, Ajay
Bonney, Denise
Veys, Paul
Rao, Kanchan
Chiesa, Robert
Al-Hajj, Muhammad
Cordoba, Shaun P.
Onuoha, Shimobi
Kotsopoulou, Ekaterini
Khokhar, Nushmia Z.
Pule, Martin
Peddareddigari, Vijay G. R.
BLOOD, 2018, 132
[39] Adct-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase 1 Trial
Jain, Nitin
Jabbour, Elias
Aldoss, Ibrahim
Konopleva, Marina
Short, Nicholas
Stein, Anthony S.
Pemmaraju, Naveen
Thompson, Philip A.
Ravandi, Farhad
Kantarjian, Hagop
BLOOD, 2022, 140
[40] Outcomes of CD19 chimeric antigen receptor T cell followed by haploidentical hematopoietic stem-cell transplantation in relapsed/refractory B-cell acute lymphoblastic leukemia with IKZF1 deletion
Ni, Fang
Yin, Elaine Tan Su
Zhou, Linghui
Zhao, Houli
Luo, Yi
Shi, Jimin
Hu, Yongxian
Huang, He
BONE MARROW TRANSPLANTATION, 2022, 57 (02) : 326 - 328

← 1 2 3 4 5 →